Gastric neoplasm

Researchers are testing whether a combination of two immunotherapy drugs, tremelimumab and durvalumab, can treat MSI-high gastric or gastroesophageal junction cancer without immediate surgery. The trial enrolls adults with resectable tumors and gives the drugs before a planned op…

This phase 2 trial is testing whether a therapeutic cancer vaccine called AST-301 can safely train the immune system to fight HER2-expressing gastric cancer cells. The study enrolls people with stage II or III gastric cancer who have already had surgery and completed standard adj…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard chemotherapy before surgery helps patients with advanced stomach or gastroesophageal junction cancer. About 116 participants will receive either the combo or chemo alone for three cycles before…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab first, followed by a combination of ramucirumab and paclitaxel, can shrink tumors and delay progression in people with advanced gastric or gastroesophageal junction adenocarcinoma. The study enrolls…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This study tests whether a new drug called zanidatamab, combined with chemotherapy and sometimes another drug (tislelizumab), works better than the current standard treatment for advanced HER2-positive stomach and esophageal cancers. About 920 adults whose cancer has spread or ca…

This study tests a drug called zolbetuximab that targets a protein (CLDN18.2) found in many stomach and gastroesophageal junction tumors. The drug is given alone or with chemotherapy and/or immunotherapy to see how well it controls tumor growth. The study includes 143 adults with…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…

This study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…

This early-phase trial tests an experimental drug called BI 765049 in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest dose people can tolerate and to see if the drug helps the imm…

This trial tests a new drug called BAY 1895344 (elimusertib) combined with standard chemotherapy (FOLFIRI) in people with advanced or metastatic stomach or colorectal cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants receive th…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This trial is testing whether giving a PD-1 immunotherapy drug after surgery can help people with a specific type of stomach cancer (MSI-H) live longer without the cancer coming back. Participants who had surgery to remove their stomach cancer will be randomly assigned to receive…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This phase 2 trial is testing whether adding surufatinib (a targeted therapy that blocks blood vessel growth) to standard immunotherapy and chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment is given befor…

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrin…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This trial tests whether combining an immunotherapy drug (tislelizumab) with standard chemotherapy and heated chemotherapy delivered directly into the abdomen can shrink tumors and improve survival in people with stomach cancer that has spread to the lining of the abdomen. The st…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer without their cancer growing. About 500 adults…

This study tests a surgical technique for early stomach cancer that combines a camera in the abdomen (laparoscopy) with a flexible tube down the throat (endoscopy). Doctors inject a fluorescent dye near the tumor to highlight the first lymph nodes that might contain cancer. If th…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…

This study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…

This Phase 3 trial tests a new drug called AZD0901 against standard chemotherapy in 592 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The study me…

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive th…

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This Phase 3 trial tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced HER2-negative stomach or gastroesophageal junction cancer live longer. About 626 participants who have not had prior chemotherapy will re…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, an…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…

This early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This study tests a new drug called anvumetostat, alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that lack the MTAP gene. The goal is to find the safest dose and see if it shrinks tumors. About 329 people will take part across multiple phases.

This phase 3 trial compares a newer targeted drug, trastuzumab deruxtecan, against a standard combination of two other drugs (ramucirumab and paclitaxel) in 490 adults with HER2-positive stomach or gastro-esophageal junction cancer that has worsened after initial treatment with t…

This study explores whether a blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide if patients with stage II-III gastric cancer need chemotherapy after surgery. About 65 patients will be followed for three years to see if those with no detectable ctDNA c…

This phase 2 trial is testing a five-drug combination for people with advanced esophageal, stomach, or gastroesophageal junction cancer that has worsened after initial treatment. The combination includes immune cells from healthy donors, two immunotherapy drugs, and two standard …

This study looks at whether surgery to remove stomach cancer that has spread to the abdomen can help people live longer when done after chemotherapy. About 300 adults whose cancer responded well to initial treatment will be randomly assigned to either have surgery plus more thera…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study tests a new device called the Luso-Cor esophageal stent for closing leaks (fistulas) that can happen after weight-loss or cancer surgery on the stomach or esophagus. About 180 adults will be enrolled and their outcomes compared to those treated with standard stents or …

This Phase 3 trial tests whether adding zolbetuximab, an antibody that targets the Claudin 18.2 protein found on many stomach tumors, to standard chemotherapy can delay cancer progression in people with advanced stomach or gastroesophageal junction cancer. About 565 adults whose …

This study is testing whether a newer, less invasive type of stomach cancer surgery (using just one or a few small cuts) is as safe and effective as the standard approach. The trial involves 108 people with advanced stomach cancer who need their stomach partially removed. The mai…

This study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the …

This early-phase study is testing whether a diet low in the amino acid leucine, given for just three days before surgery, is safe for people with stomach cancer. Researchers will check blood amino acid levels, immune cell changes, and any side effects. The goal is to see if this …

This early-phase trial tests a new drug called IDX-1197 combined with standard chemotherapy (XELOX or irinotecan) in 87 people with advanced stomach cancer. The main goal is to find the safest dose and check for side effects. It is not yet known if the combination works better th…

This phase 2 trial tests whether a combination of lenvatinib, pembrolizumab, and chemotherapy (FLOT) can shrink stomach tumors before surgery and prevent recurrence afterward. It involves 43 adults with untreated, non-metastatic stomach cancer. The main goal is to see how many pa…

This study tests a new antibody drug, S095029, combined with the immunotherapy pembrolizumab in people with advanced stomach or gastro-esophageal junction cancer that has a specific genetic feature (MSI-H/dMMR). The trial aims to see if the combination is safe and can shrink tumo…

This pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increa…

This study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemorad…

This phase 2 trial tests whether adding an experimental drug (ONO-4578) to standard immunotherapy (nivolumab) and chemotherapy helps people with advanced HER2-negative stomach cancer. About 226 participants who have not had prior chemotherapy will receive either the experimental …

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…

This early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…

This study tests a new genetic vaccine called Nous-209, given together with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced MSI-H or dMMR solid tumors (colorectal, gastric, or gastro-esophageal junction cancers). The vaccine is designed to train the immun…

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This phase II trial tests a combination of chemotherapy drugs for stomach cancer that has spread to the lining of the abdomen. About 40 adults will receive standard intravenous chemo plus paclitaxel infused directly into the abdomen. The goal is to see if this approach improves h…

This early-stage trial tests whether adding two drugs—pucotenlimab (an immunotherapy) and lenvatinib (a targeted therapy)—to standard chemotherapy (SOX) can shrink tumors better than chemotherapy alone in people with advanced HER2-negative stomach or gastroesophageal junction can…

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab before standard chemotherapy and radiation can help prevent stomach cancer from coming back. It includes 40 people with operable stomach cancer that has either a specific DNA repair problem (mismat…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This study aimed to see if adding two immune-boosting drugs (zimberelimab and domvanalimab) to standard chemotherapy could help people with operable stomach or esophageal cancer. All participants would have received the treatment before and after surgery, then be followed for up …

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard FLOT chemotherapy can improve outcomes for people with stage III gastric cancer. About 138 participants will receive either the combo or chemo alone before surgery. The main goal is to see if t…

This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or slow disease progres…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug …

This phase II trial tests a combination of three drugs—fruquintinib, sintilimab, and SOX (S-1 plus oxaliplatin)—as a pre-surgery treatment for people with stage IV gastric cancer that cannot be fully removed. The goal is to shrink the tumor enough to allow complete surgical remov…

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…

This study tests a new drug (RC48-ADC) combined with immunotherapy (toripalimab) and either chemotherapy or another targeted drug (trastuzumab) as a first treatment for people with advanced stomach cancer. About 201 adults aged 18-75 with HER2-positive or HER2-negative stomach ca…

This early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal ju…

Researchers test whether flushing the biopsy needle with heparin, a blood thinner, helps collect more and better tissue from solid abdominal tumors during endoscopic ultrasound-guided fine needle biopsy. They also test whether using a microsieve to prepare the tissue improves the…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…

This study is testing whether a customized molecular test can identify which people with intestinal metaplasia—a condition that can precede stomach cancer—are at very high risk of developing the disease. Researchers will collect blood and stomach tissue samples from 500 adults ag…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study looks at whether a special type of CT scan (spectral CT) combined with a tumor marker (MSI status) can more accurately predict if stomach cancer has spread to nearby lymph nodes. Researchers will compare the CT results with the actual lymph node findings after surgery …

This study tests a new magnetic tracer, FerroTrace, to find sentinel lymph nodes in people with stomach or esophageal cancer. About 60 participants will receive the tracer before standard treatment, and doctors will compare its accuracy to current methods. The goal is to see if t…

This study tests whether an artificial intelligence system (called CADe) can help doctors spot early stomach cancers during endoscopy. About 260 people at high risk for stomach cancer will have two endoscopies: one without the AI and one with it. The goal is to see if the AI redu…

This study looks at whether testing stool (feces) for certain DNA changes and bacteria genes can help find stomach cancer early. Researchers will follow 3000 people, including those with and without cancer, to see how well the test works. The goal is to improve early diagnosis an…

This study tests whether curcumin, a compound found in turmeric, can prevent stomach cancer in people with chronic atrophic gastritis or gastric intestinal metaplasia. About 50 participants will receive either curcumin or a placebo for a period, and researchers will measure chang…

This study screens 500 adults in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and gastric cancer. Those who test positive receive free treatment with a three-drug combination (VOQUEZNA® Triple Pak®) for 14 days. The goal is to see i…

This study screens people in South Florida for H. pylori, a stomach infection that can lead to chronic gastritis, ulcers, and even stomach cancer. Those who test positive receive treatment, and the study compares at-home breath testing versus in-person retesting to confirm the in…

This study tests whether personalized screening can prevent stomach and colon cancer in 40,000 healthy adults aged 50-75. For stomach cancer, researchers combine a test for H. pylori bacteria with a blood test for stomach damage to identify high-risk individuals. For colon cancer…

This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…

This study tests a telehealth program designed to help people improve their diet and quality of life after surgery for stomach or esophagus cancer. About 53 patients who have had curative surgery will receive virtual sessions with diet support. The goal is to see if the program i…

This trial tests whether a combination of acetaminophen and ibuprofen (Maxigesic) given through an IV can control pain better than acetaminophen alone after laparoscopic or robotic stomach cancer surgery. About 90 adults undergoing this surgery will be randomly assigned to one of…

This study compares two minimally invasive surgeries for cancer at the top of the stomach or where the stomach meets the esophagus: removing only the upper part (proximal gastrectomy) versus removing the entire stomach (total gastrectomy). The goal is to see which approach leads …

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This study looks at whether a structured care plan right after surgery can improve quality of life and recovery for people with gastric cancer who had chemotherapy or radiation before surgery. About 264 adults aged 18-80 will take part. The goal is to see if this approach reduces…

This trial compares two surgeries—removing part of the stomach (resection) versus creating a bypass—to relieve blockages in advanced stomach cancer. It includes 63 patients with obstructed tumors. The main goal is to see which procedure better eases symptoms like nausea and vomit…

This study tests whether using a FitBit and a mobile app can help people recover at home after surgery for stomach, liver, colon, or other GI cancers. About 107 patients will either use the devices plus standard care, or standard care alone. The app tracks activity and symptoms, …

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at how a specific gene change (called hMLH1 hypermethylation) affects stomach cancer. Researchers will study 245 patients who had stomach cancer surgery to find links between lifestyle, genetics, and how the cancer behaves. The goal is to better understand why so…

This study examines the extra costs of doing an upper endoscopy (stomach scope) at the same time as a routine colonoscopy for colon cancer screening. Researchers will also analyze the overall economic burden of treating stomach cancer. Data from 250 patients will be collected fro…

This study explores whether artificial intelligence can predict if stomach cancer will come back within a year after surgery. Researchers will analyze CT scans and clinical data from 900 patients with locally advanced gastric cancer. The goal is to build a model that helps doctor…

This study looks at 80 patients with both locally advanced gastric cancer and high blood pressure. Researchers want to see if taking beta-blockers (a common blood pressure drug) alongside standard cancer treatment leads to better tumor shrinkage compared to other blood pressure d…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study follows 197 people with stage II-III gastric cancer who had surgery. Researchers want to see if using a blood test (ctDNA) to guide post-surgery treatment works as well as standard chemotherapy. The goal is to learn if some patients can safely receive less intense trea…

This study looks at whether using a small camera (laparoscopy) to see if stomach cancer has spread inside the belly can help doctors choose the best treatment. About 968 people with stage III stomach cancer will be randomly assigned to either standard care or care guided by this …

This study is testing whether an artificial intelligence model can predict duodenal stump leakage, a serious complication that can occur after laparoscopic surgery to remove stomach cancer. The research involves 1200 participants who have had or will have this surgery. The goal i…

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This study looks at how a patient's age influences the type of treatment they receive for stomach cancer that can be removed with surgery, and how that affects their survival. Researchers will analyze genetic information from tumors to better understand why age matters. The goal …

This study looks at whether leaving a breathing tube in for 24-48 hours after gastric cancer surgery can lower complications in patients who also have severe obstructive sleep apnea. Researchers will compare two groups of 240 patients: one with standard tube removal and one with …

This study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …

This study tracks 500 adults with conditions like acid reflux, achalasia, or complications after weight-loss surgery. Participants choose either a newer endoscopic procedure (done through a scope) or standard surgery. Researchers will compare how well each approach controls sympt…

This study follows 438 older adults (60+) who had surgery for gastric cancer. Researchers want to understand how diet changes over time and how those changes relate to frailty. Participants complete surveys at discharge and at 1, 3, and 6 months after surgery. The goal is to desi…

This study examines whether men and women with gastric cancer receive different care in Germany. Researchers will analyze data from 75,000 patients treated between 2017 and 2021, looking at survival rates, complications, and treatment approaches. The goal is to identify gender-ba…